Insights

Precision Immunotherapy Focus Affini-T Therapeutics is a leading precision immunotherapy company targeting oncogenic driver mutations, such as KRAS, to develop potentially curative therapies for solid tumors. This focus on specialized treatments presents a sales opportunity for engaging with healthcare providers seeking innovative solutions.

Expanding Leadership Team With recent key appointments of executives like the Chief Business Officer and Chief Financial Officer, Affini-T is strengthening its leadership team with industry veterans. This expansion presents a sales opportunity for service providers offering tailored solutions to support a rapidly growing biotech company.

Launch of Novel Therapies The recent launch of KRAS G12V by Affini-T demonstrates the company's commitment to developing novel preclinical therapies for solid tumors. This product launch opens a sales opportunity for collaborations with treatment centers looking to stay at the forefront of cutting-edge therapies.

Financially Strong and Growing Affini-T's healthy financial status, with revenue in the range of $10M - $50M and significant funding of $175M, indicates a robust growth trajectory. This financial stability offers a sales opportunity for financial service providers looking to partner with a thriving biotech company.

Distinct Technological Advancements Affini-T leverages advanced technologies in its therapeutic modalities, such as T Cell Receptor (TCR) based approaches and gene editing platforms. The company's technological edge presents a sales opportunity for tech providers offering complementary solutions to enhance Affini-T's research and development processes.

Affini-T Therapeutics Tech Stack

Affini-T Therapeutics uses 8 technology products and services including Sucuri, Blackline, MySQL, and more. Explore Affini-T Therapeutics's tech stack below.

  • Sucuri
    Content Delivery Network
  • Blackline
    Corporate Performance Management
  • MySQL
    Database
  • Microsoft
    Miscellaneous
  • Smartsheet
    Project Management
  • X-XSS-Protection
    Security
  • Google Tag Manager
    Tag Management
  • Expensify
    Travel And Expense Management

Media & News

Affini-T Therapeutics's Email Address Formats

Affini-T Therapeutics uses at least 1 format(s):
Affini-T Therapeutics Email FormatsExamplePercentage
First.Last@affinittx.comJohn.Doe@affinittx.com
49%
First@affinittx.comJohn@affinittx.com
2%
First.Last@affinittx.comJohn.Doe@affinittx.com
49%

Frequently Asked Questions

Where is Affini-T Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Affini-T Therapeutics's main headquarters is located at 100 Forge Rd Watertown, Massachusetts 02472 US. The company has employees across 2 continents, including North AmericaEurope.

What is Affini-T Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Affini-T Therapeutics's official website is affinittx.com and has social profiles on LinkedIn.

How much revenue does Affini-T Therapeutics generate?

Minus sign iconPlus sign icon
As of November 2024, Affini-T Therapeutics's annual revenue reached $15M.

What is Affini-T Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Affini-T Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Affini-T Therapeutics have currently?

Minus sign iconPlus sign icon
As of November 2024, Affini-T Therapeutics has approximately 88 employees across 2 continents, including North AmericaEurope. Key team members include Chief Scientific Officer: L. V.Chief Medical Officer: D. N.Chief Financial Officer: K. B.. Explore Affini-T Therapeutics's employee directory with LeadIQ.

What industry does Affini-T Therapeutics belong to?

Minus sign iconPlus sign icon
Affini-T Therapeutics operates in the Biotechnology Research industry.

What technology does Affini-T Therapeutics use?

Minus sign iconPlus sign icon
Affini-T Therapeutics's tech stack includes SucuriBlacklineMySQLMicrosoftSmartsheetX-XSS-ProtectionGoogle Tag ManagerExpensify.

What is Affini-T Therapeutics's email format?

Minus sign iconPlus sign icon
Affini-T Therapeutics's email format typically follows the pattern of . Find more Affini-T Therapeutics email formats with LeadIQ.

How much funding has Affini-T Therapeutics raised to date?

Minus sign iconPlus sign icon
As of November 2024, Affini-T Therapeutics has raised $175M in funding. The last funding round occurred on Mar 22, 2022 for $175M.
Affini-T Therapeutics

Affini-T Therapeutics

Biotechnology ResearchMassachusetts, United States51-200 Employees

Affini-T is a leading clinical stage precision immunotherapy company targeting oncogenic driver mutations, beginning with KRAS, to develop potentially curative therapies for patients with solid tumors.  We are advancing two distinct T Cell Receptor (TCR) based therapeutic modalities encompassing adoptive cellular therapies and bispecific T Cell Engagers, each designed to harness T cell immunity with unprecedented precision and potency against solid tumors. Our most advanced TCR T-cell therapies are built based on state-of-the-art engineering, synthetic biology, and gene editing proprietary platforms overcoming the challenges of addressing solid tumors. Our T Cell therapies have high specificity and the multi-faceted ability to strike and persist within the solid tumors.  Building on the world-class innovation inherent in our leadership team, founders and differentiating technologies, we are powered to develop transformational medicines that last.

Section iconCompany Overview

Headquarters
100 Forge Rd Watertown, Massachusetts 02472 US
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
51-200

Section iconFunding & Financials

  • $175M

    Affini-T Therapeutics has raised a total of $175M of funding over 1 rounds. Their latest funding round was raised on Mar 22, 2022 in the amount of $175M.

  • $10M$50M

    Affini-T Therapeutics's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $175M

    Affini-T Therapeutics has raised a total of $175M of funding over 1 rounds. Their latest funding round was raised on Mar 22, 2022 in the amount of $175M.

  • $10M$50M

    Affini-T Therapeutics's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.